Mount Yale Investment Advisors LLC Acquires 11,632 Shares of Kenvue Inc. (NYSE:KVUE)

Mount Yale Investment Advisors LLC raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 50.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,599 shares of the company’s stock after purchasing an additional 11,632 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Kenvue were worth $739,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Grove Bank & Trust increased its stake in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter valued at approximately $29,000. Riverview Trust Co purchased a new stake in shares of Kenvue during the third quarter valued at approximately $30,000. Fortitude Family Office LLC increased its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in Kenvue in the 3rd quarter worth approximately $35,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE:KVUE opened at $21.36 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a 50-day simple moving average of $22.05 and a two-hundred day simple moving average of $21.85. The firm has a market capitalization of $40.95 billion, a PE ratio of 38.84, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the company posted $0.31 EPS. The firm’s revenue was down .4% on a year-over-year basis. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.84%. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

Several analysts have commented on KVUE shares. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. UBS Group lowered their target price on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.